Source-checked research · source-checked guide

Oral GLP-1 Availability: Products and Access Routes

By the Clinic Scout Editorial Team · Updated

Editorial illustration for Oral GLP-1 Availability: Products and Access Routes: layered research documents and evidence cards

Sources checked 2026-08-21 · Prices checked · Prices and terms can change.

Quick answer

Oral GLP-1 availability is product- and route-specific. As of August 21, 2026, FDA-label captures identify four tablet identities: Rybelsus, Ozempic, Wegovy, and Foundayo. Manufacturer sources show prescription routes for some, but neither approval nor a route proves coverage, prescribing, fulfillment, or local stock. [S3] [S4] [S5] [S7] [S9]

Verified claims

Each statement below is bound to its numbered source.

  1. As of August 21, 2026, FDA-label captures identify Rybelsus, Ozempic, Wegovy, and Foundayo tablet identities, while manufacturer sources show prescription routes for some; neither approval nor a route establishes personal coverage, prescribing, fulfillment, or local stock.34579
  2. FDA captures identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron under different label revisions and broad use categories.345101112
  3. Rybelsus is an oral semaglutide tablet identity in FDA revision 213051Orig1s030, whose captured indication section includes type 2 diabetes.310
  4. Ozempic tablets are oral semaglutide under FDA revision 213051Orig1s030, and the captured NovoCare surface lists an Ozempic pill pathway that requires a prescription.31013
  5. Wegovy tablets are oral semaglutide under FDA revision 215256s033 in captured weight-reduction and cardiovascular-risk-reduction label categories, and captured first-party surfaces describe a prescription pathway.47811
  6. Foundayo is oral orforglipron under FDA original label 220934Orig1s000 in a captured weight-reduction category, and a dated manufacturer release describes launch routes.25912
  7. The captured Rybelsus/Ozempic FDA label is filename 213051Orig1s030lbl.pdf, and its recent-major-changes block dates indications to October 2025 and dosage and administration to December 2025.310
  8. The captured Wegovy FDA label is filename 215256s033lbl.pdf, and its recent-changes table includes 2025 changes and a February 2026 warnings-and-precautions removal.411
  9. The captured Foundayo FDA label is filename 220934Orig1s000lbl.pdf and identifies oral orforglipron with initial U.S. approval in 2026.512
  10. Current captures establish manufacturer-pharmacy pathways for Wegovy and Ozempic pills and a dated manufacturer launch statement for Foundayo, but no nationwide inventory database.7913
  11. The captured NovoCare page says a licensed health care provider determines whether a GLP-1 medicine is right and may prescribe.7
  12. Product-specific NovoCare captures identify Wegovy and Ozempic prescription paths, while a page listing does not prove stock for every request.713
  13. The captured Wegovy pharmacy path places prescription receipt and processing before account, payment, delivery, or pickup steps.7
  14. Lilly's April 1, 2026 release said Foundayo prescriptions were accepted immediately through LillyDirect and shipping would begin April 6.9
  15. The Foundayo release used prospective 'followed shortly after' wording for broader U.S. retail availability.9
  16. The Foundayo release included telehealth providers in its prospective broader-availability statement.9
  17. Product-specific NovoCare captures identify Wegovy and Ozempic pill pathways and require prescriptions; the article excludes promotional prices, savings terms, strengths, and tracked links.713
  18. The captured product-specific Wegovy pharmacy page requires a prescription and places receipt and processing before account, payment, delivery, or pickup.7
  19. The manufacturer site identifies Wegovy as a pill and prescription medication, while the FDA label supplies the formal oral identity.48
  20. Lilly's April 1, 2026 Foundayo release said prescriptions were accepted immediately through LillyDirect, shipping would begin April 6, and broader retail and telehealth availability would follow shortly after.9
  21. FDA and Lilly prescribing-information captures identify Foundayo as oral orforglipron in a captured weight-reduction labeled-use category.2512
  22. The captured FDA document identifies Rybelsus and Ozempic tablets as oral semaglutide GLP-1 receptor agonists under one revision in a type 2 diabetes category.310
  23. The NovoCare capture lists an Ozempic pill pathway and says a prescription is required.13
  24. The captured NovoCare page says a licensed health care provider discusses health history and goals and may prescribe if the provider determines a GLP-1 medicine is right.7
  25. The April 1, 2026 Foundayo release included telehealth providers in prospective broader-availability language.9
  26. Current FDA labels identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron under revisions 213051Orig1s030, 215256s033, and 220934Orig1s000.345101112
  27. FDA captures identify Rybelsus, Ozempic tablets, and Wegovy tablets as distinct branded semaglutide tablet identities with different captured label categories.341011
  28. The dated Foundayo release describes immediate LillyDirect prescription acceptance, April 6 shipping, and later broader retail and telehealth routes, not universal current inventory.9
  29. Captured NovoCare product pages require prescriptions, and the Wegovy product page places prescription receipt and processing before delivery or pickup steps.713
  30. The captured manufacturer-pharmacy page assigns the suitability and prescription decision to a licensed health care provider rather than guaranteeing a positive result from intake.7
  31. Captured FDA filenames distinguish the Rybelsus/Ozempic tablet label, Wegovy label, and Foundayo original label.345101112
  32. Oral and subcutaneous evidence is formulation-specific and does not establish interchangeability or current availability.17
  33. For Medicare, coverage requires the exact plan formulary; this guide makes no price claim.15
  34. A phase 2 oral-orforglipron trial predicts neither individual outcomes nor current availability.16
  35. The captured current Rybelsus/Ozempic label lists nausea, abdominal pain, diarrhea, decreased appetite, vomiting, and constipation as common adverse reactions.10
  36. The captured current Wegovy label lists nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis as common adverse reactions.11
  37. The captured current Foundayo label lists nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, and hair loss as common adverse reactions.12
  38. The captured label lists are product-specific and are not used to compare reaction rates or judge individual suitability.101112
  39. FDA warns of fraudulent compounded GLP-1 products and directs online buyers to state-licensed pharmacies.14
  40. Pipeline literature does not establish current approval, prescription routes, coverage, fulfillment, or stock.18

Facts to compare

Source-bound facts from this guide
QuestionPublished factEvidence
Product statusAs of August 21, 2026, FDA-label captures identify Rybelsus, Ozempic, Wegovy, and Foundayo tablet identities, while manufacturer sources show prescription routes for some; neither approval nor a route establishes personal coverage, prescribing, fulfillment, or local stock.Mapped claim
Product statusFDA captures identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron under different label revisions and broad use categories.Mapped claim
Product statusWegovy tablets are oral semaglutide under FDA revision 215256s033 in captured weight-reduction and cardiovascular-risk-reduction label categories, and captured first-party surfaces describe a prescription pathway.Mapped claim
Product statusFoundayo is oral orforglipron under FDA original label 220934Orig1s000 in a captured weight-reduction category, and a dated manufacturer release describes launch routes.Mapped claim
Product statusThe captured Rybelsus/Ozempic FDA label is filename 213051Orig1s030lbl.pdf, and its recent-major-changes block dates indications to October 2025 and dosage and administration to December 2025.Mapped claim
Product statusThe captured Wegovy FDA label is filename 215256s033lbl.pdf, and its recent-changes table includes 2025 changes and a February 2026 warnings-and-precautions removal.Mapped claim
Product statusThe captured Foundayo FDA label is filename 220934Orig1s000lbl.pdf and identifies oral orforglipron with initial U.S. approval in 2026.Mapped claim
CostProduct-specific NovoCare captures identify Wegovy and Ozempic pill pathways and require prescriptions; the article excludes promotional prices, savings terms, strengths, and tracked links.Mapped claim

What to verify

Confirm

  • Uses current primary evidence.
  • Separates verified facts from unknowns.
  • Maps decision-bearing claims to captured source text.

Do not assume

  • Terms, prices, labels, and coverage can change.
  • Individual outcomes and eligibility cannot be inferred from general evidence.
  • The page cannot replace clinician, plan, or pharmacy verification.

Quick evidence check

What the sources establish

  • Uses current primary evidence.
  • Separates verified facts from unknowns.
  • Maps decision-bearing claims to captured source text.

What still needs verification

  • Terms, prices, labels, and coverage can change.
  • Individual outcomes and eligibility cannot be inferred from general evidence.
  • The page cannot replace clinician, plan, or pharmacy verification.

The short answer

The search for **oral glp-1 availability** sounds like a single yes-or-no question, but it contains several different questions. A product can have a current FDA label and still require a clinician’s prescription. A manufacturer can describe a pharmacy or launch route without proving that every location has stock. A payer can list a product without approving a particular request. A pharmacy can receive a prescription without being ready to dispense it.

The useful answer is a product-and-route record. First identify the exact branded tablet and active ingredient. Next check the current FDA label revision and broad labeled-use category. Then separate the clinical evaluation and prescription result from the route that may process the prescription. Finally, verify payer status and dispensing-location status independently. A blank field stays unknown rather than becoming an assumed “available.”

The fresh FDA captures identify Rybelsus and Ozempic tablets as oral semaglutide products, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron. Their captured label identifiers are different, and the labels do not place every product in the same broad use category. [S3] [S4] [S5] [S10] [S11] [S12]

This guide compares identities and evidence routes; it does not rank the products. It offers no dosing or administration instructions and does not decide whether any product is suitable for an individual. It also does not recommend a clinician, pharmacy, telehealth company, insurer, manufacturer-direct channel, or treatment path.

Six meanings of availability.

These states should never collapse into one badge. “FDA-labeled” is not “prescribed.” “Prescribed” is not “covered.” “Covered” is not “processed.” “Processed” is not “in stock.” A national or manufacturer page can identify a route, but only the organization that owns the next decision can supply that next status.

The short answer
Availability stateEvidence that answers it
Product identityCurrent official label naming the brand, active ingredient, and oral tablet form.
Labeled-use categoryCurrent official label, read for the exact branded product rather than a molecule-level assumption.
Clinical and prescription stateThe responsible clinician’s actual evaluation and prescription result.
Distribution routeA dated first-party statement identifying a manufacturer, pharmacy, retail, or telehealth pathway.
Coverage and processingThe exact payer’s current response and the intended pharmacy’s transaction state.
Local inventoryA dated answer from the specific dispensing location for the exact product.

Current oral GLP-1 product identities

The product name matters because semaglutide appears under multiple branded tablet identities, while orforglipron appears under a different brand and FDA application. Searching only for “oral semaglutide” or “GLP-1 pill” can hide which label, use category, prescription, payer entry, and pharmacy item is actually being discussed.

Product identity and captured route comparison.

Current oral GLP-1 product identities
Product identityWhat the current capture establishes
Rybelsus tabletsSemaglutide tablets for oral use under FDA label revision `213051Orig1s030`; the captured indications place Rybelsus and Ozempic tablets in a type 2 diabetes category. [S3] [S10]
Ozempic tabletsSemaglutide tablets for oral use under FDA revision `213051Orig1s030`; a separate NovoCare capture identifies an Ozempic pill pathway and requires a prescription. [S3] [S10] [S13]
Wegovy tabletsSemaglutide tablets for oral use under FDA label revision `215256s033`; the complete tablet indications include adult weight-reduction and cardiovascular-risk-reduction categories. First-party surfaces also describe a prescription pathway. [S4] [S7] [S8] [S11]
Foundayo tabletsOrforglipron tablets for oral use under original FDA label `220934Orig1s000`; the label includes a weight-reduction category for specified adults, and a dated manufacturer release describes launch routes. [S2] [S5] [S9] [S12]

Why the FDA label revision belongs in the record

An FDA label is versioned. A product name without the captured application or supplement identifier can point to an older document, a different formulation, or a page that has not incorporated later changes. For this check, the revision identifier is read directly from the captured FDA-label filename and retained with the evidence date.

The Rybelsus and Ozempic tablet capture uses FDA filename `213051Orig1s030lbl.pdf`, giving revision identifier `213051Orig1s030`. The new Drugs@FDA capture explicitly displays that filename; the label’s “Recent Major Changes” block dates the captured indications change to October 2025 and the captured dosage-and-administration change to December 2025. [S3] [S10]

The Wegovy tablet capture uses FDA filename `215256s033lbl.pdf`, giving revision identifier `215256s033`. The new Drugs@FDA capture explicitly displays that filename; the captured recent-changes table includes indications and dosage-and-administration changes dated in 2025 and a warnings-and-precautions removal dated February 2026. [S4] [S11]

The Foundayo capture uses FDA filename `220934Orig1s000lbl.pdf`, giving original-label identifier `220934Orig1s000`; the new Drugs@FDA capture explicitly displays that filename, and the label identifies the product as oral orforglipron with initial U.S. approval in 2026. [S5] [S12]

These identifiers are evidence-control fields, not instructions for use. The article deliberately does not reproduce strengths, schedules, switching instructions, or administration requirements. Anyone reviewing the record can use the identifier to confirm that the exact captured label—not a general blog post—owns the product identity claim.

Availability routes are not interchangeable

A route tells where an evaluation, prescription, or dispensing process may occur. It does not prove that a product is clinically suitable, that a prescription will be issued, that a plan will cover it, or that a pharmacy will have it when needed. The current packet captured manufacturer pharmacy pathways for Wegovy and Ozempic pills and a dated manufacturer launch statement for Foundayo. It did not capture a nationwide inventory database. [S7] [S9] [S13]

Route comparison without a recommendation.

Availability routes are not interchangeable
RouteWhat can and cannot be inferred
Clinician office or telehealth evaluationMay produce a clinical decision and perhaps a prescription. A service page, appointment, or intake does not guarantee either result. The captured NovoCare page says a licensed health care provider determines whether a GLP-1 medicine is right and may prescribe. [S7]
Manufacturer pharmacy surfaceCan identify products the captured page accepts and a processing pathway. Product-specific NovoCare captures identify Wegovy and Ozempic prescription paths; a page listing does not prove stock for every request. [S7] [S13]
Named product pharmacy pathwayCan show what happens after a prescription is sent. The Wegovy capture says the prescription must be received and processed before account, payment, delivery, or pickup steps follow. [S7]
Manufacturer-direct launch routeCan document a dated launch statement. Lilly’s April 1, 2026 release said Foundayo prescriptions were accepted immediately and shipping would begin April 6 through LillyDirect. [S9]
U.S. retail pharmacyRequires confirmation from the exact location or dispensing network. The Foundayo release used prospective “followed shortly after” wording for broad retail availability; it did not prove every store’s current inventory. [S9]
Telehealth providerCan be an evaluation and prescription channel if the service and clinician are applicable. The Foundayo release named telehealth as a planned broad route, but that does not endorse a service or guarantee prescribing, coverage, or supply. [S9]

Wegovy and Ozempic on the captured NovoCare pathway

The product-specific NovoCare captures identify Wegovy and Ozempic pill pathways and state that prescriptions are required. The article uses those pages only as evidence that the named manufacturer-pharmacy surfaces exist for those products. It excludes all promotional prices, savings terms, strengths, and tracked destination links. [S7] [S13]

The product-specific Wegovy pharmacy capture provides a clearer sequence. It says Wegovy requires a prescription, asks for the prescription to be sent to NovoCare Pharmacy if a health care provider finds it appropriate, and says receipt and processing occur before account, payment, delivery, or pickup steps. [S7]

The independent manufacturer product site identifies Wegovy as a pill and calls it a prescription medication. The FDA label, rather than the marketing page, controls the formal product identity and revision used in this guide. [S4] [S8]

Readers comparing oral semaglutide background can use the Wegovy oral semaglutide guide. That page and this one are educational records, not endorsements, price promises, or substitutes for an exact prescription and pharmacy response.

Foundayo has a dated launch boundary

Foundayo needs a date-aware description because the fresh route evidence is a manufacturer announcement. The Lilly release is dated April 1, 2026. It says prescriptions were accepted immediately through LillyDirect, shipping would begin April 6, and broader availability through U.S. retail pharmacies and telehealth providers would follow shortly after. [S9]

The wording must remain prospective where the release was prospective. “Would follow shortly after” is not the same as a current readback from every retail chain, every telehealth service, or every state. The August 21 capture confirms what the dated release said; it does not transform the release into a nationwide inventory report.

The FDA original label and Lilly prescribing-information capture independently identify Foundayo as oral orforglipron and place it in a weight-reduction category for specified adults. Those sources support product identity and labeled-use boundaries, not an individual prescription result. [S2] [S5] [S12]

A careful record therefore has separate fields for “manufacturer route announced,” “prescription accepted by route,” “shipping or pickup state,” “retail location contacted,” and “current inventory response.” A positive entry in the first field does not fill the others.

Rybelsus and Ozempic tablets share a label but not an assumption

The captured FDA document names both Rybelsus and Ozempic tablets as oral semaglutide and places them under one revision identifier. It also says they are GLP-1 receptor agonists in a type 2 diabetes indication category. [S3] [S10]

Sharing an active ingredient and label document does not make brand names interchangeable in an access record. The exact prescription, payer entry, pharmacy item, and labeled product name still matter. A search result about oral semaglutide may omit that identity. A pharmacy may need the precise prescribed product rather than the molecule category. A plan’s response for one product cannot be copied into the other product’s field without exact-plan evidence.

The NovoCare Ozempic product capture identifies an Ozempic pill/tablet pathway and says a prescription is required. It does not provide a reader-specific prescription, payer result, or stock confirmation, and it does not establish the status of every retail pharmacy. [S13]

For the broader difference between a plan’s support services and actual benefit status, review insurance support versus coverage and insurance support versus self-pay. Those comparisons organize administrative terms; they do not decide a personal claim.

Approval, coverage, and inventory answer different questions

A frequent availability error is to start with a true product fact and stretch it into a different owner’s decision. The correction is simple: record the owner, exact question, evidence date, and unresolved state.

Keep each evidence owner in its lane.

This separation also prevents a negative result from spreading too far. A plan denial does not say that a product is not FDA-labeled. A pharmacy stockout does not say that no route has stock. A clinician’s decision not to prescribe does not establish what another person’s plan covers. A manufacturer route page does not establish treatment suitability.

Approval, coverage, and inventory answer different questions
Evidence ownerStatus it can actually provide
FDA labelExact product identity, oral form, active ingredient, broad labeled-use category, and captured revision.
ClinicianEvaluation result, clinical suitability decision, and whether a prescription was issued.
Health plan or pharmacy benefit managerCurrent formulary, restriction, authorization, claim, or benefit response for the exact product and recorded use.
Manufacturer or manufacturer pharmacyTerms and processing states for its named channel on a specified date.
Retail or dispensing pharmacyPrescription receipt, clarification, processing, transfer, fulfillment, and inventory for that location and time.
Search engine or general articleDiscovery context only; it cannot replace any owner’s current decision.

Personal coverage requires exact-plan evidence

No current-run source in this packet contains a reader’s plan document, member benefit, formulary result, authorization decision, or processed claim. The guide therefore makes no personal coverage conclusion.

A coverage record should name the exact plan and pharmacy-benefit channel, the exact branded product, the use recorded in the request, the document or response date, any restriction or authorization status, and a reference number when supplied. “GLP-1 covered” is too broad because labels, benefit categories, employer designs, and uses can differ.

For a dedicated coverage framework, use the oral GLP-1 insurance coverage guide. It can help structure questions, but only the exact payer’s current response can fill the personal coverage field.

Local inventory requires an exact dispensing response

National availability language is useful for discovering possible routes, but inventory changes by product, dispensing organization, location, and time. The current FDA labels have no universal stock field. The manufacturer pages describe their own surfaces and processes. The Foundayo release describes a dated launch plan. None proves that an unnamed nearby pharmacy has the exact tablet today.

The GLP-1 shortage and availability guide provides a broader way to separate public supply signals from an exact pharmacy response. Neither page guarantees inventory.

Telehealth is a route, not a product outcome

A telehealth page can describe an evaluation format. It cannot decide in advance whether the responsible clinician will find a product suitable or issue a prescription. The captured NovoCare product page states that a licensed health care provider discusses health history and goals and may prescribe if the provider determines a GLP-1 medicine is right. [S7]

The Foundayo release included telehealth providers in its prospective broader-availability sentence. That is evidence of a manufacturer-announced route category as of April 1, 2026, not a directory, endorsement, licensure determination, prescription promise, coverage promise, or inventory report. [S9]

For neutral background on remote prescription workflows, see how online GLP-1 prescriptions work and the online provider comparison page. This article does not rank the services listed elsewhere and does not direct a reader to enroll.

Build one dated availability record

Oral GLP-1 availability record.

An “unknown” is a valid result. It prevents a search snippet, launch announcement, reachable product page, or another location’s answer from becoming an unsupported claim. When a response changes, keep the prior date rather than silently overwriting the history.

Build one dated availability record
Record fieldNeutral entry format
Exact productBrand, active ingredient, oral tablet identity, and FDA label revision.
Labeled-use categoryBroad category from the exact current label; no individual inference.
Clinical routePractice or service, responsible clinician if disclosed, evaluation format, and date.
Prescription stateNot evaluated, pending, prescribed, not prescribed, sent, transferred, or unknown.
Distribution routeManufacturer-direct, manufacturer pharmacy, retail pharmacy, telehealth-linked pharmacy, or unknown.
Payer stateNot checked, listed, excluded, restricted, authorization pending, approved, denied, claim processed, or unknown.
Dispensing stateNot received, received, clarification needed, processing, transferred, unavailable, ready, or unknown.
Evidence dateDate and source for the label, route statement, payer response, and pharmacy response.

A nonclinical verification checklist

This checklist is administrative. It does not advise anyone to start, stop, switch, request, or use a medication, and it does not screen for medical eligibility.

  1. Write the exact brand and active ingredient being investigated.
  2. Confirm that the evidence refers to tablets for oral use rather than an injectable formulation.
  3. Record the current FDA label filename and revision identifier.
  4. Record only the broad labeled-use category; do not infer individual suitability.
  5. Identify whether the route is a clinician office, telehealth evaluation, manufacturer channel, or retail pharmacy.
  6. Keep evaluation, prescription, payer, pharmacy-processing, and inventory states separate.
  7. Ask the exact payer about the exact branded product and recorded use.
  8. Ask the intended dispensing pharmacy whether the prescription was received and what state it is in.
  9. Treat a manufacturer launch statement as dated route evidence, not universal stock.
  10. Treat public pricing and savings text as separate, date-bound program information; do not use it as a coverage response.
  11. Mark unresolved fields unknown.
  12. Date every answer and preserve the organization that supplied it.

Research limitation: the failed position-10 capture

The exact-query search returned a tenth result on a Facebook video page, but the fresh direct attempt at `2026-08-21T11:44:06Z` failed with `HTTP Error 403: Forbidden`. The failed raw capture is retained with SHA-256 `ea0ed569bc26f0116b3d35ada64820459c1fe694a00741f86e044c7c0e299257`.

No page body, outline, entities, or direct quotes were obtained. The result contributes no product, approval, prescription, route, coverage, or inventory claim. “Unavailable” applies only to that capture attempt on August 21, 2026; it does not say that the page, video, or any product was unavailable at another time or through another surface.

Context beyond the availability record

Pill versus injection.

Oral and subcutaneous evidence is formulation-specific, not interchangeability or current-availability proof. [S17]

Cost versus coverage.

For Medicare, coverage requires the exact plan formulary; this guide makes no price claim. [S15]

Effectiveness and trial context.

A phase 2 oral-orforglipron trial predicts neither individual outcomes nor current availability. [S16]

High-level safety and side effects.

These captured label lists are product-specific; do not compare reaction rates or use them to judge individual suitability. [S10] [S11] [S12]

Counterfeit-source risk.

FDA warns of fraudulent compounded GLP-1 products and directs online buyers to state-licensed pharmacies. [S14]

Pipeline and access challenges.

Pipeline literature does not establish current approval, prescription routes, coverage, fulfillment, or stock. [S18]

Dosing remains outside this availability guide.

Strengths, schedules, switching directions, and administration instructions remain outside this guide.

Context beyond the availability record
ProductCommon adverse reactions in the captured current label
Rybelsus/Ozempic tabletsNausea, abdominal pain, diarrhea, decreased appetite, vomiting, and constipation. [S10]
Wegovy tabletsNausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis. [S11]
Foundayo tabletsNausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, and hair loss. [S12]

Update policy

Evidence checked 2026-08-21. FDA labels, manufacturer channels, launch statements, plan formularies, authorization states, pharmacy processing, and local inventory can change. Recheck the exact product and route with the organization that owns each decision.

The position-10 direct capture was unavailable only at 2026-08-21T11:44:06Z because the fresh attempt returned HTTP 403. It remains closed to all claims unless a later run obtains and separately binds the body.

Frequently asked questions

Which oral GLP-1 products are identified in the current FDA captures?

The current labels identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron. Their captured revision identifiers are `213051Orig1s030`, `215256s033`, and `220934Orig1s000`, respectively. [S3] [S4] [S5] [S10] [S11] [S12]

Does an FDA label mean the product is in stock near me?

No. A label establishes product identity and labeled information. It does not report inventory at a particular dispensing pharmacy, for a specific location, or at the time of reading.

Are Rybelsus, Ozempic tablets, and Wegovy tablets the same product?

The FDA captures identify all three as semaglutide tablets, but they are distinct branded product identities and the captured label categories differ. Keep the exact brand attached to the prescription, payer, and pharmacy record. [S3] [S4] [S10] [S11]

Is Foundayo currently available through every retail pharmacy?

This packet cannot support that claim. Lilly’s April 1, 2026 release said prescriptions were accepted immediately through LillyDirect, shipping would begin April 6, and broader retail and telehealth availability would follow shortly after. That dated launch statement is not universal current inventory. [S9]

Can NovoCare Pharmacy fill Wegovy without a prescription?

The captured NovoCare product pages say a prescription is required. The Wegovy product page places prescription receipt and processing before account, payment, delivery, or pickup steps. They do not guarantee that any individual request will be prescribed or fulfilled. [S7] [S13]

Does a telehealth intake guarantee an oral GLP-1 prescription?

No. An intake or appointment is an evaluation route. The captured manufacturer-pharmacy page says a licensed health care provider determines whether a GLP-1 medicine is right and may prescribe; it does not promise a positive result. [S7]

Does a prescription mean insurance will cover the product?

No. Prescription and coverage are separate states. The exact plan or pharmacy-benefit channel must provide the current formulary, restriction, authorization, or claim response for the exact product and recorded use.

Does plan coverage guarantee that a pharmacy can dispense it?

No. Payer approval and pharmacy processing are different. The intended dispensing pharmacy still has to receive and process the prescription and provide its own current fulfillment or inventory state.

Why record the FDA label revision identifier?

The identifier binds the product claim to a specific captured FDA document. In this packet, the current filenames distinguish the Rybelsus/Ozempic tablet label, Wegovy label, and Foundayo original label. [S3] [S4] [S5] [S10] [S11] [S12]

Does this guide recommend one oral product or access route?

No. It compares identity and evidence ownership only. It recommends no medication, product, manufacturer, provider, pharmacy, telehealth service, insurer, or treatment and gives no dosing or individualized medical advice.

Sources and what they support

  1. Yale MedicineBackground source for the guide boundary.Yale Medicine — published page, 2026-08Checked 2026-08-21
  2. Eli Lilly and CompanySupports: Foundayo is oral orforglipron under FDA original label 220934Orig1s000 in a captured weight-reduction category, and a dated manufacturer release describes launch routes. · FDA and Lilly prescribing-information captures identify Foundayo as oral orforglipron in a captured weight-reduction labeled-use category.Eli Lilly and Company — PDF document, 2026-08Checked 2026-08-21
  3. U.S. Food and Drug AdministrationSupports: As of August 21, 2026, FDA-label captures identify Rybelsus, Ozempic, Wegovy, and Foundayo tablet identities, while manufacturer sources show prescription routes for some; neither approval nor a route establishes personal coverage, prescribing, fulfillment, or local stock. · FDA captures identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron under different label revisions and broad use categories. · Rybelsus is an oral semaglutide tablet identity in FDA revision 213051Orig1s030, whose captured indication section includes type 2 diabetes. · Ozempic tablets are oral semaglutide under FDA revision 213051Orig1s030, and the captured NovoCare surface lists an Ozempic pill pathway that requires a prescription. · The captured Rybelsus/Ozempic FDA label is filename 213051Orig1s030lbl.pdf, and its recent-major-changes block dates indications to October 2025 and dosage and administration to December 2025. · The captured FDA document identifies Rybelsus and Ozempic tablets as oral semaglutide GLP-1 receptor agonists under one revision in a type 2 diabetes category. · Current FDA labels identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron under revisions 213051Orig1s030, 215256s033, and 220934Orig1s000. · FDA captures identify Rybelsus, Ozempic tablets, and Wegovy tablets as distinct branded semaglutide tablet identities with different captured label categories. · Captured FDA filenames distinguish the Rybelsus/Ozempic tablet label, Wegovy label, and Foundayo original label.U.S. Food and Drug Administration — PDF document, 2026-08Checked 2026-08-21
  4. U.S. Food and Drug AdministrationSupports: As of August 21, 2026, FDA-label captures identify Rybelsus, Ozempic, Wegovy, and Foundayo tablet identities, while manufacturer sources show prescription routes for some; neither approval nor a route establishes personal coverage, prescribing, fulfillment, or local stock. · FDA captures identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron under different label revisions and broad use categories. · Wegovy tablets are oral semaglutide under FDA revision 215256s033 in captured weight-reduction and cardiovascular-risk-reduction label categories, and captured first-party surfaces describe a prescription pathway. · The captured Wegovy FDA label is filename 215256s033lbl.pdf, and its recent-changes table includes 2025 changes and a February 2026 warnings-and-precautions removal. · The manufacturer site identifies Wegovy as a pill and prescription medication, while the FDA label supplies the formal oral identity. · Current FDA labels identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron under revisions 213051Orig1s030, 215256s033, and 220934Orig1s000. · FDA captures identify Rybelsus, Ozempic tablets, and Wegovy tablets as distinct branded semaglutide tablet identities with different captured label categories. · Captured FDA filenames distinguish the Rybelsus/Ozempic tablet label, Wegovy label, and Foundayo original label.U.S. Food and Drug Administration — PDF document, 2026-08Checked 2026-08-21
  5. U.S. Food and Drug AdministrationSupports: As of August 21, 2026, FDA-label captures identify Rybelsus, Ozempic, Wegovy, and Foundayo tablet identities, while manufacturer sources show prescription routes for some; neither approval nor a route establishes personal coverage, prescribing, fulfillment, or local stock. · FDA captures identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron under different label revisions and broad use categories. · Foundayo is oral orforglipron under FDA original label 220934Orig1s000 in a captured weight-reduction category, and a dated manufacturer release describes launch routes. · The captured Foundayo FDA label is filename 220934Orig1s000lbl.pdf and identifies oral orforglipron with initial U.S. approval in 2026. · FDA and Lilly prescribing-information captures identify Foundayo as oral orforglipron in a captured weight-reduction labeled-use category. · Current FDA labels identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron under revisions 213051Orig1s030, 215256s033, and 220934Orig1s000. · Captured FDA filenames distinguish the Rybelsus/Ozempic tablet label, Wegovy label, and Foundayo original label.U.S. Food and Drug Administration — PDF document, 2026-08Checked 2026-08-21
  6. NovoCare Pharmacy / Novo NordiskBackground source for the guide boundary.NovoCare Pharmacy / Novo Nordisk — published page, 2026-08Checked 2026-08-21
  7. NovoCare Pharmacy / Novo NordiskSupports: As of August 21, 2026, FDA-label captures identify Rybelsus, Ozempic, Wegovy, and Foundayo tablet identities, while manufacturer sources show prescription routes for some; neither approval nor a route establishes personal coverage, prescribing, fulfillment, or local stock. · Wegovy tablets are oral semaglutide under FDA revision 215256s033 in captured weight-reduction and cardiovascular-risk-reduction label categories, and captured first-party surfaces describe a prescription pathway. · Current captures establish manufacturer-pharmacy pathways for Wegovy and Ozempic pills and a dated manufacturer launch statement for Foundayo, but no nationwide inventory database. · The captured NovoCare page says a licensed health care provider determines whether a GLP-1 medicine is right and may prescribe. · Product-specific NovoCare captures identify Wegovy and Ozempic prescription paths, while a page listing does not prove stock for every request. · The captured Wegovy pharmacy path places prescription receipt and processing before account, payment, delivery, or pickup steps. · Product-specific NovoCare captures identify Wegovy and Ozempic pill pathways and require prescriptions; the article excludes promotional prices, savings terms, strengths, and tracked links. · The captured product-specific Wegovy pharmacy page requires a prescription and places receipt and processing before account, payment, delivery, or pickup. · The captured NovoCare page says a licensed health care provider discusses health history and goals and may prescribe if the provider determines a GLP-1 medicine is right. · Captured NovoCare product pages require prescriptions, and the Wegovy product page places prescription receipt and processing before delivery or pickup steps. · The captured manufacturer-pharmacy page assigns the suitability and prescription decision to a licensed health care provider rather than guaranteeing a positive result from intake.NovoCare Pharmacy / Novo Nordisk — published page, 2026-08Checked 2026-08-21
  8. Novo NordiskSupports: Wegovy tablets are oral semaglutide under FDA revision 215256s033 in captured weight-reduction and cardiovascular-risk-reduction label categories, and captured first-party surfaces describe a prescription pathway. · The manufacturer site identifies Wegovy as a pill and prescription medication, while the FDA label supplies the formal oral identity.Novo Nordisk — published page, 2026-08Checked 2026-08-21
  9. Eli Lilly and CompanySupports: As of August 21, 2026, FDA-label captures identify Rybelsus, Ozempic, Wegovy, and Foundayo tablet identities, while manufacturer sources show prescription routes for some; neither approval nor a route establishes personal coverage, prescribing, fulfillment, or local stock. · Foundayo is oral orforglipron under FDA original label 220934Orig1s000 in a captured weight-reduction category, and a dated manufacturer release describes launch routes. · Current captures establish manufacturer-pharmacy pathways for Wegovy and Ozempic pills and a dated manufacturer launch statement for Foundayo, but no nationwide inventory database. · Lilly's April 1, 2026 release said Foundayo prescriptions were accepted immediately through LillyDirect and shipping would begin April 6. · The Foundayo release used prospective 'followed shortly after' wording for broader U.S. retail availability. · The Foundayo release included telehealth providers in its prospective broader-availability statement. · Lilly's April 1, 2026 Foundayo release said prescriptions were accepted immediately through LillyDirect, shipping would begin April 6, and broader retail and telehealth availability would follow shortly after. · The April 1, 2026 Foundayo release included telehealth providers in prospective broader-availability language. · The dated Foundayo release describes immediate LillyDirect prescription acceptance, April 6 shipping, and later broader retail and telehealth routes, not universal current inventory.Eli Lilly and Company — published page, 2026-08Checked 2026-08-21
  10. U.S. Food and Drug AdministrationSupports: FDA captures identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron under different label revisions and broad use categories. · Rybelsus is an oral semaglutide tablet identity in FDA revision 213051Orig1s030, whose captured indication section includes type 2 diabetes. · Ozempic tablets are oral semaglutide under FDA revision 213051Orig1s030, and the captured NovoCare surface lists an Ozempic pill pathway that requires a prescription. · The captured Rybelsus/Ozempic FDA label is filename 213051Orig1s030lbl.pdf, and its recent-major-changes block dates indications to October 2025 and dosage and administration to December 2025. · The captured FDA document identifies Rybelsus and Ozempic tablets as oral semaglutide GLP-1 receptor agonists under one revision in a type 2 diabetes category. · Current FDA labels identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron under revisions 213051Orig1s030, 215256s033, and 220934Orig1s000. · FDA captures identify Rybelsus, Ozempic tablets, and Wegovy tablets as distinct branded semaglutide tablet identities with different captured label categories. · Captured FDA filenames distinguish the Rybelsus/Ozempic tablet label, Wegovy label, and Foundayo original label. · The captured current Rybelsus/Ozempic label lists nausea, abdominal pain, diarrhea, decreased appetite, vomiting, and constipation as common adverse reactions. · The captured label lists are product-specific and are not used to compare reaction rates or judge individual suitability.U.S. Food and Drug Administration — regulatory document, 2026-08Checked 2026-08-22
  11. U.S. Food and Drug Administration / DailyMed, U.S. National Library of MedicineSupports: FDA captures identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron under different label revisions and broad use categories. · Wegovy tablets are oral semaglutide under FDA revision 215256s033 in captured weight-reduction and cardiovascular-risk-reduction label categories, and captured first-party surfaces describe a prescription pathway. · The captured Wegovy FDA label is filename 215256s033lbl.pdf, and its recent-changes table includes 2025 changes and a February 2026 warnings-and-precautions removal. · Current FDA labels identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron under revisions 213051Orig1s030, 215256s033, and 220934Orig1s000. · FDA captures identify Rybelsus, Ozempic tablets, and Wegovy tablets as distinct branded semaglutide tablet identities with different captured label categories. · Captured FDA filenames distinguish the Rybelsus/Ozempic tablet label, Wegovy label, and Foundayo original label. · The captured current Wegovy label lists nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis as common adverse reactions. · The captured label lists are product-specific and are not used to compare reaction rates or judge individual suitability.U.S. Food and Drug Administration / DailyMed, U.S. National Library of Medicine — regulatory document, 2026-08Checked 2026-08-22
  12. U.S. Food and Drug AdministrationSupports: FDA captures identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron under different label revisions and broad use categories. · Foundayo is oral orforglipron under FDA original label 220934Orig1s000 in a captured weight-reduction category, and a dated manufacturer release describes launch routes. · The captured Foundayo FDA label is filename 220934Orig1s000lbl.pdf and identifies oral orforglipron with initial U.S. approval in 2026. · FDA and Lilly prescribing-information captures identify Foundayo as oral orforglipron in a captured weight-reduction labeled-use category. · Current FDA labels identify Rybelsus and Ozempic tablets as oral semaglutide, Wegovy tablets as oral semaglutide, and Foundayo tablets as oral orforglipron under revisions 213051Orig1s030, 215256s033, and 220934Orig1s000. · Captured FDA filenames distinguish the Rybelsus/Ozempic tablet label, Wegovy label, and Foundayo original label. · The captured current Foundayo label lists nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, and hair loss as common adverse reactions. · The captured label lists are product-specific and are not used to compare reaction rates or judge individual suitability.U.S. Food and Drug Administration — regulatory document, 2026-08Checked 2026-08-22
  13. NovoCare Pharmacy / Novo NordiskSupports: Ozempic tablets are oral semaglutide under FDA revision 213051Orig1s030, and the captured NovoCare surface lists an Ozempic pill pathway that requires a prescription. · Current captures establish manufacturer-pharmacy pathways for Wegovy and Ozempic pills and a dated manufacturer launch statement for Foundayo, but no nationwide inventory database. · Product-specific NovoCare captures identify Wegovy and Ozempic prescription paths, while a page listing does not prove stock for every request. · Product-specific NovoCare captures identify Wegovy and Ozempic pill pathways and require prescriptions; the article excludes promotional prices, savings terms, strengths, and tracked links. · The NovoCare capture lists an Ozempic pill pathway and says a prescription is required. · Captured NovoCare product pages require prescriptions, and the Wegovy product page places prescription receipt and processing before delivery or pickup steps.NovoCare Pharmacy / Novo Nordisk — published page, 2026-08Checked 2026-08-22
  14. U.S. Food and Drug AdministrationSupports: FDA warns of fraudulent compounded GLP-1 products and directs online buyers to state-licensed pharmacies.U.S. Food and Drug Administration — regulatory document, 2026-08Checked 2026-08-22
  15. Medicare.gov / Centers for Medicare & Medicaid ServicesSupports: For Medicare, coverage requires the exact plan formulary; this guide makes no price claim.Medicare.gov / Centers for Medicare & Medicaid Services — published page, 2026-08Checked 2026-08-22
  16. New England Journal of MedicineSupports: A phase 2 oral-orforglipron trial predicts neither individual outcomes nor current availability.New England Journal of Medicine — published page, 2026-08Checked 2026-08-22
  17. PubMed Central / CureusSupports: Oral and subcutaneous evidence is formulation-specific and does not establish interchangeability or current availability.PubMed Central / Cureus — published page, 2026-08Checked 2026-08-22
  18. PubMed / International Journal of ObesitySupports: Pipeline literature does not establish current approval, prescription routes, coverage, fulfillment, or stock.PubMed / International Journal of Obesity — published page, 2026-08Checked 2026-08-22